nach oben

Die Urologie

Erschienen in:

01.11.2006 | Leitthema

Evidenzbasierte Pharmakologische Harnsteinmetaphylaxe

verfasst von: Dr. M. Straub, R. E. Hautmann

Erschienen in: Die Urologie | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Zusammenfassung

Rund ein Viertel der Steinbildner sind hinsichtlich einer rezidivierenden Urolithiasis bzw. hochaktiven metabolischen Störung tatsächliche Hochrisikopatienten. Sie benötigen als adäquate Therapie bzw. zur Sekundärprävention eine spezifische Metaphylaxe, die sich an der metabolischen Risikosituation orientiert. Die aktuellen Therapieempfehlungen für die einzelnen Harnsteinarten werden in diesem Beitrag kurz skizziert und im Hinblick ihrer Evidenzgrundlage bewertet. Außerdem wird ein Follow-up für pharmakologisch therapierte Hochrisikosteinbildner vorgestellt.

Abdulhadi MH, Hall PM, Streem SB (1993) Can citrate therapy prevent nephrolithiasis? Urology 41: 221–224CrossRefPubMed

Allerheiligen DA, Schoeber J, Houston RE et al. (1998) Hyperparathyroidism. Am Fam Phys 57: 1795–1798

Asper R, Schmucki O (1982) Cystinuria therapy by ascorbic acid (author’s transl). Urol Int 37: 91–109PubMed

Barbey F, Joly D, Rieu P et al. (2000) Medical treatment of cystinuria: critical reappraisal of long-term results. J Urol 163: 1419–1423CrossRefPubMed

Barcelo P, Wuhl O, Servitge E et al. (1993) Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 150: 1761–1764PubMed

Berio A, Piazzi A (2001) Prophylaxia of cystine calculosis by alpha-mercaptopropionyl-glycine administered continuously or every other day. Boll Soc Ital Biol Sper 77: 35–41PubMed

Bilobrov VM, Chugaj AV (1993) Physicochemical background for ambiguity of clinical recommendations in treating phosphate nephrolithiasis. Urol Int 50: 43–46PubMed

Birwe H, Schneeberger W, Hesse A (1991) Investigations of the efficacy of ascorbic acid therapy in cystinuria. Urol Res 19: 199–201CrossRefPubMed

Blair B, Fabrizio M (2000) Pharmacology for renal calculi. Expert Opin Pharmacother 1: 435–441CrossRefPubMed

10.

Borghi L, Meschi T, Guerra A, Novarini A (1993) Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol 22 [Suppl 6]: 78–86CrossRef

11.

Butz M (1987) Alkalizitrat-Therapie bei rezidivierender Kalzium-Urolithiasis. Urologe B 27: 95–99

12.

Cochat P, Gaulier JM, Koch Nogueira PC et al. (1999) Combined liver-kidney transplantation in primary hyperoxaluria type 1. Eur J Pediatr 158 [Suppl 2]: 75–80CrossRef

13.

Cohen TD, Streem SB, Hall P (1995) Clinical effect of captopril on the formation and growth of cystine calculi. J Urol 154: 164–166CrossRefPubMed

14.

de Pauw L, Gelin M, Danpure CJ et al. (1990) Combined liver-kidney transplantation in primary hyperoxaluria type 1. Transplantation 50: 886–887PubMed

15.

Domrongkitchaiporn S, Khositseth S, Stitchantrakul W et al. (2002) Dosage of potassium citrate in the correction of urinary abnormalities in pediatric distal renal tubular acidosis patients. Am J Kidney Dis 39: 383–391PubMed

16.

Esen T, Marshall VR, Rao N, Ettinger B (2003) Medical management of urolithiasis, chap. 4. In: Segura JW, Conort P, Khoury S, Pak CY, Preminger GM, Tolley D (eds) Stone disease, 1 edn. Health Publications, Paris, pp 133–149

17.

Ettinger B, Citron JT, Livermore B, Dolman LI (1988) Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 139: 679–684PubMed

18.

Ettinger B, Pak CY, Citron JT et al. (1997) Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158: 2069–2073CrossRefPubMed

19.

Fjellstedt E, Denneberg T, Jeppsson JO, Tiselius HG (2001) A comparison of the effects of potassium citrate and sodium bicarbonate in the alkalinization of urine in homozygous cystinuria. Urol Res 29: 295–302CrossRefPubMed

20.

Gault MH, Parfrey PS, Robertson WG (1988) Idiopathic calcium phosphate nephrolithiasis. Nephron 48: 265–273PubMed

21.

Hautmann R, Terhorst B, Stuhlsatz HW, Lutzeyer W (1977) Mercaptopropionylglycine: a progress in cystine stone therapy. J Urol 117: 628–630PubMed

22.

Hesse A (2002) Urinary calculi: 1. Epidemiology, laboratory diagnosis, genetics and infections. Urologe A 41: 496–506CrossRefPubMed

23.

Hesse A, Heimbach D (1999) Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. World J Urol 17: 308–315CrossRefPubMed

24.

Hesse A, Miersch WD, Classen A et al. (1988) 2,8-Dihydroxyadeninuria: laboratory diagnosis and therapy control. Urol Int 43: 174–178PubMed

25.

Hesse A, Siener R, Heynck H, Jahnen A (1993) The influence of dietary factors on the risk of urinary stone formation. Scann Microsc 7: 1119–1127

26.

Hesse A, Tiselius HG, Jahnen A (2002) Urinary stones, 2nd edn. Karger, Basel

27.

Hofbauer J, Hobarth K, Szabo N, Marberger M (1994) Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis – a prospective randomized study. Br J Urol 73: 362–365PubMed

28.

Holmes RP (1998) Pharmacological approaches in the treatment of primary hyperoxaluria. J Nephrol 11 [Suppl 1]: 32–35PubMed

29.

Hoppe B, Langman CB (2003) A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr Nephrol 18: 986–991CrossRefPubMed

30.

Hoppe B, Latta K, von Schnakenburg C, Kemper MJ (2005) Primary hyperoxaluria – the German experience. Am J Nephrol 25: 276–281CrossRefPubMed

31.

Jacobs D, Heimbach D, Hesse A (2001) Chemolysis of struvite stones by acidification of artificial urine – an in vitro study. Scand J Urol Nephrol 35: 345–349CrossRefPubMed

32.

Jarrar K, Boedeker RH, Weidner W (1996) Struvite stones: long term follow up under metaphylaxis. Ann Urol (Paris) 30: 112–117

33.

Jendle-Bengten C, Tiselius HG (2000) Long-term follow-up of stone formers treated with a low dose of sodium potassium citrate. Scand J Urol Nephrol 34: 36–41CrossRefPubMed

34.

Kato Y, Yamaguchi S, Yachiku S et al. (2004) Changes in urinary parameters after oral administration of potassium-sodium citrate and magnesium oxide to prevent urolithiasis. Urology 63: 7–11CrossRefPubMed

35.

Kearns AE, Thompson GB (2002) Medical and surgical management of hyperparathyroidism. Mayo Clin Proc 77: 87–91PubMed

36.

Khan SR, Shevock PN, Hackett RL (1993) Magnesium oxide administration and prevention of calcium oxalate nephrolithiasis. J Urol 149: 412–416PubMed

37.

Knoll T, Janitzky V, Michel MS et al. (2003) Cystinuria – Cystine stones: Recommendations for diagnosis, therapy and follow-up. Aktuelle Urol 34: 97–101CrossRefPubMed

38.

Kohri K, Tozawa K, Hayashi Y et al. (2000) Clinical features of primary hyperparathyroidism: preoperative localization and parathyroidectory. Biomed Pharmacother 54 [Suppl 1]: 69–71CrossRefPubMed

39.

Kollars J, Zarroug AE, van Heerden J et al. (2005) Primary hyperparathyroidism in pediatric patients. Pediatrics 115: 974–980CrossRefPubMed

40.

Laerum E (1984) Metabolic effects of thiazide versus placebo in patients under long-term treatment for recurrent urolithiasis. Scand J Urol Nephrol 18: 143–149PubMed

41.

Leskovar P (1980) Current status of prevention and therapy of urinary calculi and peroral chemo-litholysis with special attention to the relationship of increased excretion of uric acid in oxalate lithiasis. Z Urol Nephrol 73: 229–239PubMed

42.

Leumann E, Hoppe B, Neuhaus T (1993) Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr Nephrol 7: 207–211CrossRefPubMed

43.

Leumann E, Hoppe B, Neuhaus T, Blau N (1995) Efficacy of oral citrate administration in primary hyperoxaluria. Nephrol Dial Transplant 10 [Suppl 8]: 14–16

44.

Lindell A, Denneberg T, Hellgren E et al. (1995) Clinical course and cystine stone formation during tiopronin treatment. Urol Res 23: 111–117CrossRefPubMed

45.

Ohkawa M, Tokunaga S, Nakashima T et al. (1992) Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. Br J Urol 69: 571–576PubMed

46.

Osborne CA, Lulich JP, Bartges JW et al. (1999) Drug-induced urolithiasis. Vet Clin North Am Small Anim Pract 29: 251–266PubMed

47.

Pak CY (1991) Citrate and renal calculi: New insights and future directions. Am J Kidney Dis 17: 420–425PubMed

48.

Pak CY, Fuller C, Sakhaee K et al. (1986) Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol 136: 1003–1008PubMed

49.

Pak CY, Sakhaee K, Fuller C (1986) Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 30: 422–428PubMed

50.

Pearle MS, Roehrborn CG, Pak CY (1999) Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. J Endourol 13: 679–685PubMed

51.

Preminger GM (1987) Pharmacologic treatment of uric acid calculi. Urol Clin North Am 14: 335–338PubMed

52.

Preminger GM, Sakhaee K, Skurla C, Pak CY (1985) Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 134: 20–23PubMed

53.

Rodman JS (1991) Prophylaxis of uric acid stones with alternate day doses of alkaline potassium salts. J Urol 145: 97–99PubMed

54.

Rodman JS (1999) Struvite stones. Nephron 81 [Suppl 1]: 50–59CrossRefPubMed

55.

Rodman JS (2002) Intermittent versus continuous alkaline therapy for uric acid stones and ureteral stones of uncertain composition. Urology 60: 378–382CrossRefPubMed

56.

Rodman JS, Mahler RJ (2000) Kidney stones as a manifestation of hypercalcemic disorders. Hyperparathyroidism and sarcoidosis. Urol Clin North Am 27: 275–285CrossRefPubMed

57.

Schneeberger W, Hesse A, Vahlensieck W (1992) Recurrent nephrolithiasis in renal tubular acidosis. Metabolic profiles, therapy and course. Urol Res 20: 98–100CrossRefPubMed

58.

Shekarriz B, Stoller ML (2002) Uric acid nephrolithiasis: current concepts and controversies. J Urol 168: 1307–1314CrossRefPubMed

59.

Siener R, Hesse A (2003) The effect of a vegetarian and different omnivorous diets on urinary risk factors for uric acid stone formation. Eur J Nutr 42: 332–337CrossRefPubMed

60.

Simmonds HA (1986) 2,8-Dihydroxyadenine lithiasis. Clin Chim Acta 160: 103–108CrossRefPubMed

61.

Straub M, Hautmann RE, Hesse A, Rinnab L (2005) Calcium oxalate stones and hyperoxaluria What is certain? What is new? Urologe A 44(11): 1315–1323CrossRefPubMed

62.

Straub M, Strohmaier WL, Berg W et al. (2005) Diagnosis and metaphylaxis of stone disease Consensus concept of the National Working Committee on Stone Disease for the Upcoming German Urolithiasis Guideline. World J Urol 23: 309–323CrossRefPubMed

63.

Streem SB, Cohen TD, Hall P (1996) Efficacy of captopril on formation and growth of cystine calculi. In: Tiselius HG (ed) Renal stones. Tiselius, Linkoping, pp 168–170

64.

Trinchieri A, Luongo P, Rovera F et al. (1994) Treatment of cystine nephrolithiasis with alpha-mercaptopropionylglycine. In: Ryall R (ed) Urolithiasis, 2nd edn. Plenum Press, New York, pp 603–604

65.

Watts RW, Morgan SH, Danpure CJ et al. (1991) Combined hepatic and renal transplantation in primary hyperoxaluria type I: clinical report of nine cases. Am J Med 90: 179–188PubMed

66.

Yendt ER, Cohanim M (1985) Response to a physiologic dose of pyridoxine in type I primary hyperoxaluria. N Engl J Med 312: 953–957PubMed

Titel: Evidenzbasierte Pharmakologische Harnsteinmetaphylaxe
verfasst von: Dr. M. Straub
R. E. Hautmann
Publikationsdatum: 01.11.2006
Verlag: Springer-Verlag
Erschienen in: Die Urologie / Ausgabe 11/2006
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI: https://doi.org/10.1007/s00120-006-1235-z

Neu im Fachgebiet Urologie

24.04.2024 | DGIM 2024 | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Evidenzbasierte Pharmakologische Harnsteinmetaphylaxe

Zusammenfassung

Neu im Fachgebiet Urologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Update Urologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2006

Der Harnleiterknochen

Berufspolitik BDU

Welche Metaphylaxemaßnahme für wen?

Urolithiasis – moderne Metaphylaxe wieder ein Thema!

Mitteilungen der DGU

Adenomatoidtumor des Hodens – eine seltene Entität

Neu im Fachgebiet Urologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Update Urologie